AstraZeneca
AstraZeneca’s head and neck cancer treatment Imfinzi falls flat in Phase III trials
December 7, 2018Medical Communications AstraZeneca, Cancer, oncology, phase III, treatment
AstraZeneca’s immunotherapy treatment Imfinzi has failed to meet its primary goal in treating head and neck cancer in the Phase …
AstraZeneca’s Imfinzi immunotherapy combo fails to show benefit in lung cancer
November 16, 2018Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a …
AstraZeneca sells off paediatric lung infection drug to Sobi for $1.5bn
November 13, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Synagis, espiratory syncytial virus, pharma, sobi
AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to respiratory …
AZ’s Farxiga shows strength in largest ever SGLT2 inhibitor cardiovascular outcomes study
November 12, 2018Research and Development, Sales and Marketing AstraZeneca, cardiovascular, farxiga, pharma
AstraZeneca has revealed new data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin) at the American Heart Association (AHA) …
Top Ten most popular articles on Pharmafile.com this week!
November 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Celgene, GSK, Novo Nordisk, politics, popular, top 10, vaccines
The biggest news this week came from Israeli biotech Zion Medical after it was announced that HIV drug Gammora was …
NICE fail to recommend AstraZeneca’s cancer drug Olaparib on cost effectiveness basis
November 9, 2018Medical Communications, Sales and Marketing AstraZeneca, NHS, NICE, UK, olaparib, pharma
Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib …
AstraZeneca sells off three drugs in deal worth $350 million
November 6, 2018Manufacturing and Production AstraZeneca, asthma, covis, deal, royalties
Anglo-Swedish multinational AstraZeneca has agreed to sell the rights to three asthma and rhinitis drugs in a deal worth $350 …
Top Ten most popular articles on Pharmafile.com this week!
November 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, GSK, ITH Pharma, J&J, JJ, NICE, Sanofi, Trump, top 10
Deals dominated the headlines this week as both Sanofi and AstraZeneca made billion dollar agreements. Meanwhile, the FDA gave magic …
AstraZeneca flogs two drug licenses in $922 million deal
October 31, 2018Research and Development, Sales and Marketing AstraZeneca, pharma
AstraZeneca has signed a deal with Grünenthal worth up to $922 million in which the latter will acquire the regional …
Top Ten most popular articles on Pharmafile.com this week
October 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, AstraZeneca, Bayer, Novartis, Samsung, Trump, biosimilars, brexit
Business, biosimilars and Brexit are the themes of this week’s top 10. While Roche signed a $1 billion deal with …
AstraZeneca halting UK investment due to Brexit uncertainty
October 15, 2018Manufacturing and Production AstraZeneca, Le Monde, UK, brexit, no-deal
The Anglo-Swedish pharma firm AstraZeneca has suspended investment into the United Kingdom, due to the uncertainty surrounding Brexit. The firm’s …
AstraZeneca chalks up European approval for Imfinzi in locally advanced, unresectable lung cancer
September 25, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MedImmune, NSCLC, lung cancer, pharma
AstraZeneca and its global biologics R&D arm MedImmune have announced the approval by the European Commission of Imfinzi (durvalumab) as …
AstraZeneca’s Farxiga cuts heart risk in type 2 diabetes patients
September 24, 2018Research and Development, Sales and Marketing AstraZeneca, diabetes, farxiga, pharma
AstraZeneca has unveiled new Phase 3 data for its SGLT2 inhibitor Farxiga (dapagliflozin), showing with the drug demonstrating positive findings …
AstraZeneca to increase presence in China
September 19, 2018Research and Development AstraZeneca, China, alibaba, governemnt, tencent
The Anglo-Swedish multinational AstraZeneca is moving towards becoming a major healthcare provider in China as part of an effort to …
FDA approves AstraZeneca’s Lumoxiti for hairy cell leukaemia (HCL)
September 17, 2018Sales and Marketing AstraZeneca, HCL, Lumoxiti, leukaemia, rare diseases
AstraZeneca’s Lumoxiti has been approved for use for the treatment of relapsed or refractory hairy cell leukemia (HCL)in adults who …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
